Last reviewed · How we verify
Sensipar after Post Transplant
Sensipar after Post Transplant is a Small molecule drug developed by Amgen. It is currently in Phase 2 development.
At a glance
| Generic name | Sensipar after Post Transplant |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients (PHASE3)
- Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation (PHASE4)
- Post Transplant Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sensipar after Post Transplant CI brief — competitive landscape report
- Sensipar after Post Transplant updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Sensipar after Post Transplant
What is Sensipar after Post Transplant?
Sensipar after Post Transplant is a Small molecule drug developed by Amgen.
Who makes Sensipar after Post Transplant?
Sensipar after Post Transplant is developed by Amgen (see full Amgen pipeline at /company/amgen).
What development phase is Sensipar after Post Transplant in?
Sensipar after Post Transplant is in Phase 2.
Related
- Manufacturer: Amgen — full pipeline
- Compare: Sensipar after Post Transplant vs similar drugs
- Pricing: Sensipar after Post Transplant cost, discount & access